Bond Fund Arbitration Results in $267,000 for Morgan Keegan Investor

An investor who filed an arbitration claim as a result of losses suffered in a Morgan Keegan bond fund that collapsed after the subprime mortgage meltdown, was recently awarded $267,711 by the Financial Industry Regulatory Authority (FINRA).

Starting in late 2007, a number of bond funds managed by Morgan Keegan began a steep decline in value as a result of heavy investments that were tied to the subprime mortgage market. Some of the Morgan Keegan funds have dropped by more than 70%.

The bond fund arbitration claim was filed on behalf of a San Francisco investor, alleging that Morgan Keegan mislead investors by indicating that it was a relatively conservative investment and failing to disclose the extent of their investment in mortgage-backed securities.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The Financial Industry Regulatory Authority, which oversees about 5,000 brokerage firms throughout the United States, ordered Morgan Keegan to repay all of the investors losses, plus interest and court costs, according to the Memphis Business Journal.

Hundreds of other similar Morgan Keegan arbitration lawsuits are currently pending against the brokerage firm that is a division of Regions Financial Corp. The cases involve several different Morgan Keegan bond funds, including the RMK Strategic Income Fund, RMK Select High Income Fund and RMK Advantage Fund.

In two other recent Morgan Keegan arbitration losses, investors were awarded$187,215 and $109,881 in compensatory damages by FINRA panels.

Morgan Keegan has acknowledged that they have already lost at least 9 cases filed by investors who lost money in their bond funds. Cumulative awards to date are believed to be about $1 million, and it has been estimated that the Morgan Keegan bond fund awards may eventually cross the $200 million mark.

1 Comments

  • AshokapathyApril 10, 2009 at 6:47 am

    May be this will make investors not to blindly accept the words of the funds and similarly make the funds more resposible and accountable. This once again proofs the power of arbitration.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.